

Anti-IL-5 (Reslizumab), Humanized Antibody

07/20

CATALOG NO.: A2167-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG4 kappa monoclonal antibody that targets IL-5. IL-5 is a proinflammatory cytokine that mediates recruitment, activation, growth, differentiation, and survival of eosinophils. Increased production of eosinophils is associated with allergic and non-allergic forms of asthma. The antibody specifically binds to the ERRR region (between amino acids 89-92) of the IL-5, which is necessary for the interaction with the IL-5 receptor located on the eosinophil cell surface. This results in inhibition of IL-5 mediated signaling, prevents maturation of the eosinophils, and eosinophil-mediated inflammation. The original drug received approval from the FDA as an add-on treatment for patients suffering from severe asthma with an eosinophilic phenotype.

ALTERNATE NAMES: CEP-38072, DCP 835, DCP-835, SCH-55700, SCH55700, EDF, TRF, IL5

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG4

SOURCE: CHO cells

IMMUNOGEN: Human IL-5

CAS NUMBER: 241473-69-8

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL5 (Mepolizumab), Humanized Antibody (A2158)
 Anti-IL-5R α (Benralizumab), Humanized Antibody (A2162)
 Anti-IgE (Omalizumab), Humanized Antibody (A2145)
 Anti-IL-4R α (Dupilumab), Human IgG4 Antibody (A2148)
 Anti-TNF- α (Certolizumab Pegol), Humanized Antibody (A2142)

FOR RESEARCH USE ONLY! Not to be used on humans.